Research has shown that Brilacidin has a high residence time on the surface of the eye with negligible systemic exposure, suggesting that Brilacidin has the potential to treat ophthalmic infections, such as conjunctivitis and keratitis, with a limited dosing regimen. Additionally, a recent study of Brilacidin has shown promising results in preliminary testing of middle ear (otitis media) infection, one of the most common pediatric illnesses and also a leading cause of conductive hearing loss.
Leo Ehrlich, chief executive officer at Cellceutix, said, "After undertaking an intense due diligence process to identify the best formulator for the job, Dr. Reddy's was the clear choice as they have shown a deep understanding of what we want to accomplish. Their recent acquisition of OctoPlus in the Netherlands was a big addition to their already highly talented team as OctoPlus specializes in complex formulations. We are extremely optimistic about Brilacidin for ophthalmic and ocular indications based upon research to date and look forward to having this potentially game-changing drug in more clinical trials."
Commenting on this development, Dr. R Ananthanarayanan, president, PSAI Business, Dr. Reddy's said, "Dr. Reddy's CPS has extensive knowledge in manufacturing and formulating anti-infective therapeutics. We are already working with Cellceutix on the manufacturing of Prurisol and are excited to work with them on the development of Brilacidin. Our expertise in both APIs and formulation development will assist Cellceutix in the clinical progression of Brilacidin."